Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650117 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00650117: Completed Phase 1 study, sponsored by Mylan Pharmaceuticals.
NCT00650117 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00650117, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the effect of three different types of occlusive overlays on the drug delivery of Fentanyl Transdermal Systems, 25 mcg/h manufactured for Mylan Pharmaceuticals Inc. by Mylan Technologies Inc., and Duragesic, 25 mcg/h manufactured for Janssen Pharmaceutica by ALZA Corporation. The acute irritation of each type of overlay worn with each fentanyl treatment was also assessed after patch removal.
Interventions
- DRUG Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
- DRUG Duragesic 25 mcg/h + Scotch Duct Tape (3M)
- DRUG Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
- DRUG Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
- DRUG Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-10 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
What the finished NCT00650117 record still lists
NCT00650117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 5 interventions - of which Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M) is the first listed.
NCT00650117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00650117 about?
NCT00650117 is a clinical study titled "Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System". The objective of this study was to investigate the effect of three different types of occlusive overlays on the drug delivery of Fentanyl Transdermal Systems, 25 mcg/h manufactured for Mylan Pharmaceuticals Inc. by Mylan Technologies Inc., and Duragesic, 25 mcg/h manufactured for Janssen Pharmaceuti...
What is the current status of trial NCT00650117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-10. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00650117?
The interventions under investigation include: Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M) (DRUG), Duragesic 25 mcg/h + Scotch Duct Tape (3M) (DRUG), Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M) (DRUG), Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M) (DRUG), Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M) (DRUG).
Who is sponsoring clinical trial NCT00650117?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00650117's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia